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Introduction—Cystic fibrosis (CF) is a multi-organ disorder characterized by chronic sinopulmonary infections and inflammation. Many patients with CF suffer from repeated pulmonary
exacerbations that are predictors of worsened long-term morbidity and mortality. There are no
reliable markers that associate with the onset or progression of an exacerbation or pulmonary
deterioration. Previously, we found that the Mirc1/Mir17–92a cluster which is comprised of 6
microRNAs (Mirs) is highly expressed in CF mice and negatively regulates autophagy which in
turn improves CF transmembrane conductance regulator (CFTR) function. Therefore, here we
sought to examine the expression of individual Mirs within the Mirc1/Mir17–92 cluster in human
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cells and biological fluids and determine their role as biomarkers of pulmonary exacerbations and
response to treatment.
Methods—Mirc1/Mir17–92 cluster expression was measured in human CF and non-CF plasma,
blood-derived neutrophils, and sputum samples. Values were correlated with pulmonary function,
exacerbations and use of CFTR modulators.
Results—Mirc1/Mir17–92 cluster expression was not significantly elevated in CF neutrophils
nor plasma when compared to the non-CF cohort. Cluster expression in CF sputum was
significantly higher than its expression in plasma. Elevated CF sputum Mirc1/Mir17–92 cluster
expression positively correlated with pulmonary exacerbations and negatively correlated with lung
function. Patients with CF undergoing treatment with the CFTR modulator Ivacaftor/Lumacaftor
did not demonstrate significant change in the expression Mirc1/Mir17–92 cluster after six months
of treatment.

Author Manuscript

Conclusions—Mirc1/Mir17–92 cluster expression is a promising biomarker of respiratory status
in patients with CF including pulmonary exacerbation. Published by Elsevier B.V. on behalf of
European Cystic Fibrosis Society.
Keywords
Cystic fibrosis; MicroRNA; Mir17–92a; Biomarker; Correlation; Pulmonary exacerbation

1. Introduction
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Cystic fibrosis (CF) is a multi-organ disease caused by mutations of the cystic fibrosis
transmembrane conductance regulator (CFTR) chloride channel. Patients with CF
characteristically suffer from repeated episodes of acute worsening in respiratory symptoms
and decline in lung function termed a pulmonary exacerbation (PEx) [1]. Many definitions
of PEx have been proposed [2], but regardless of the designation used, these clinical events
are associated with progressive long-term deterioration of lung function and heightened
morbidity and mortality [3,4]. While a number of biomarkers based on inflammatory
markers in CF have been suggested, relevant biomarkers associated with exacerbation or
decline in lung function have not been developed for clinical use. Current efforts are
attempting to predict and identify PEx earlier to be able to more promptly provide treatment
with antimicrobials and anti-inflammatory agents [5]. Yet, there are no reliable diagnostic or
prognostic risk-related markers associated with PEx. Therefore, identifying biomarkers that
can reflect the existence of an exacerbation at an early stage would provide an invaluable
opportunity for early detect PEx, to avoid further physiologic and immunologic injury, and
prevent the need for costly medical care, such as hospitalization.
Biomarkers are anatomical, physiological, biochemical or imaging features that can be used
for diagnosis, monitoring disease progression, or response to treatment. An ideal biomarker
should be stable and easy to measure, cost efficient and consistent across gender and ethnic
groups. To date, none of the available biomarkers in CF satisfy all of these criteria. The
major limitations of markers are low specificity, sensitivity, and false positive results.
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MicroRNAs (Mirs) are endogenous, evolutionarily conserved small non-coding RNA that
have been shown to be effective tools to study the biology of diseases and to have great
potential as novel diagnostic and prognostic biomarkers with high specificity and sensitivity
[6]. Circulating Mirs are short non-coding RNAs involved in biological and pathological
processes of every cell type. Mirs have many necessary features of ideal biomarkers. Mirs
are stable in various biological fluids, such as plasma, serum, saliva, milk, cerebrospinal
fluid. Particularly, the expression of serum Mirs is firmly linked to various diseases. Mirs are
considered potential biomarkers for several chronic disorders due to their stability in the
circulation, and are both disease-and tissue-specific, which makes them attractive circulatory
biomarkers [7,8]. In addition, the quantity of Mirs can be easily estimated by various
methods, such as qRT-PCR, microarray, hybridization and deep-sequencing. qRT-PCR
(quantitative real time polymerase chain reaction) is the most common, reliable and
available, inexpensive method used for quantifying the small amount of miRNAs with the
highest sensitivity and specificity [9,10].

Author Manuscript

Mirs act primarily through degradation of target mRNA with subsequent decrease or loss of
expression of encoded proteins. The Mir17–92 family maps to human chromosome 13 and
encodes for the Mirc1/Mir17–92 cluster (Mir17, Mir18a, Mir19a, Mir20a, Mir19b-1,
Mir92a) and two paralogs (Mir106a, Mir106b) [11]. We have recently found that the
expression of Mir17 and Mir20a within the Mirc1/Mir17–92 cluster is elevated in CF
macrophages from F508del mice and humans. These two Mirs target several essential
autophagy proteins such as Atg5, Atg12, Atg7 and Atg16 [12,13]. We have confirmed that
the upregulation of Mir17 and Mir20a is associated with down-regulation of their predicted
autophagy targets contributing to weak autophagy activity in murine macrophages.
Restoring the level of Mir17 and Mir20a to normal levels in vivo by intra-tracheal
administration of specific antagomirs to live CF mice improves autophagy, controls
infection, and reduces pneumonia [13]. Notably, in vitro, Mir17 and Mir20a antagomirs
ameliorate CFTR function via the activation of autophagy [13]. Our published data suggest
that targeting Mir17 and Mir20a improves several clinical symptoms in patients with CF.
However, it is not clear if these Mirs are elevated in human samples and if their level
correlates with clinical symptoms and change in response to treatment. Hence, in the current
study, we determined that the Mirc1/Mir17–92 cluster is expressed broadly in human cells
including neutrophils and in biological fluids including plasma and sputum. In addition, the
most striking finding is that Mir cluster expression in sputum positively correlated with
clinical symptoms such as PEx.

2. Methods
Author Manuscript

2.1. Ethics statement
All human subjects were recruited as approved by the Institutional Review Board (IRB) of
Nationwide Children’s Hospital (IRB15-00611 and IRB12-00405). All subjects underwent
written consent for the procedures including all adult subjects provided informed consent,
and a parent or guardian of any child participant provided informed consent on their behalf
along with written assent from children.
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Male and female children older than 12 years and adult patients with CF were recruited from
the CF clinic in either a state of baseline health or during the onset of a PEx. The diagnosis
of CF was confirmed by the presence of two CF causing mutations on genetic blood testing
and/or an elevated sweat chloride test. Data including patient demographics, medications,
hospitalizations for PEx, and relevant clinical factors were collected in a database upon
recruitment. Age and gender-matched healthy controls were recruited through Clinical
Research Services. The demographics of subjects enrolled in this study are listed in Table 1.
The control population was older and had more females, but subjects undergoing Ivacaftor/
Lumacaftor treatment were not matched to healthy controls, and tended to be younger
skewing the overall cohort. The CF subjects had moderate lung disease as shown by forced
expiratory volume in 1 s (FEV1)% predicted based on American Thoracic Society criteria,
[14] and the majority were pancreatic insufficient. The majority of the CF cohort had at least
one copy of the F508del mutation.
2.3. Study parameters
Subject outcomes were stratified based upon Mirc1/Mir17–92 cluster expression. The
occurrence of a PEx was the primary outcome measure which was defined by clinicians, and
verified according to a previously published definition [15]. The outcome of lung function
was measured FEV1 and forced vital capacity (FVC) on pulmonary function testing during
routine clinical visits. Percent predicted measurements and z scores for FEV1 and FVC were
derived from reference equations [16,17]. Nutritional status was determined by body mass
index (BMI), which was calculated based on clinical measurements made by pulmonary
dieticians during routine clinical visits.

Author Manuscript

2.4. Sample collection
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Whole blood samples were obtained and plasma was isolated via centrifugation and frozen
at −80 °C. Human neutrophils were then isolated and purified by negative selection. Briefly,
blood was transferred to 50 ml conical tube and 50 μl of an antibody cocktail added per ml
of blood (Stemcell Technologies, Vancouver, BC, Canada), plus 50 μl of magnetic beads per
ml of blood. The sample was incubated 5 min at room temperature, then PBS-EDTA was
added up to 50 ml, the tube was placed in the magnet for 10 min, the supernatant was
transferred to a new tube and magnetic beads were added at the same amount of the previous
step. The sample was placed 5 min in the magnet and the supernatant was collected. The
cells were centrifuged at 600 ×g, and re-suspended in 1 ml of HBSS plus 1% of FBS before
further experimentation. Sputum samples were obtained by spontaneous expectoration into
sterile containers, aliquoted in Trizol, and frozen at −80 °C.
2.5. Quantitative real-time PCR (qRT-PCR) for expression of Mirs
Total RNA was isolated from neutrophils lysed in Trizol (Invitrogen Life Technologies,
15596-026) via chloroform (Fisher Scientific, 268320010), isopropanol (Fisher Scientific,
BP2618-212), and glycogen (Fisher Scientific, 10814010). Total RNA from plasma and
sputum samples was isolated using the miRNeasy Mini Kit (Qiagen, 217004). Expression of
mature Mir17, Mir18a, Mir19a, Mir19b, Mir20a, Mir92a, Mir101, and SNORD48/RNU48
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(as an endogenous control for human neutrophils) or cel-mir-39, cel-mir-54, and cel-mir238
(Thermo Fisher Scientific, 000200, 001361, and 000248, spike-in controls for plasma and
sputum samples) were analyzed by first converting the RNA to cDNA using specific primers
(Applied Biosystems, Assay ID 2308, 2422, 395, 396, 580, 431, 002253, 001232,
respectively) with the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems,
4366596). PCR was conducted according to the manufacturer’s guidelines. For qRT-PCR,
cDNA was primed with specific TaqMan primers listed above and assayed using TaqMan
Universal PCR MasterMix (Applied Biosystems, 4304437) and Applied Biosystems ABI
7900HT real-time PCR system. Expression was calculated as relative copy numbers. Ct
values of each Mir were subtracted from the average Ct of the internal (SNORD48/RNU48)
or spike-in (cel-mir-39, -54, and -238) control, and the resulting ΔCt was used in the
equation: relative copy numbers = (2−ΔΔCt) [13,18].

Author Manuscript

2.6. Statistical analysis
All statistical analyses were performed using GraphPad Prism software (version 7.0) and R
3.4.1. Clinical outcomes included hospitalization for PEx, number of antibiotic courses,
BMI, FEV1% predicted, and FVC% predicted. Mir expression was correlated with each
clinical outcome using Spearman’s rank correlation coefficient (rho). Mann-Whitney U tests
were used for comparisons of independent samples. Wilcoxon signed-rank tests were used
for within patient comparisons of the pre-and post-Ivacaftor/Lumacaftor group. Statistical
significance was defined as an unadjusted p value <0.05. Age and gender matched healthy
controls were used as able in the analysis. Analysis was performed on negative dCT
measurements using the average of Mir238, Mir54, and Mir39 as control measurements.

3. Results
Author Manuscript

3.1. The expression of Mirc1/Mir17–92 cluster is not significantly elevated in neutrophils
derived from CF patients
We have recently demonstrated that the Mirc1/Mir17–92 cluster is elevated in CF mouse
model and in human CF macrophages [13]. To determine if this finding was specific to
macrophages or more broadly expressed, we examined Mirc1/Mir17–92 cluster expression
in neutrophils isolated from blood of 5 patients with CF and 8 age-matched, healthy
controls. There was no significant difference in cluster expression between CF and non-CF
neutrophils (Fig. 1A). Together, our published and recent findings herein demonstrate that
the expression of specific Mirs within the Mirc1/Mir17–92 is significantly elevated in
macrophages but not neutrophils from CF patients.

Author Manuscript

3.2. CF patients have elevated Mirc1/Mir17–92 cluster expression in sputum and not
plasma
Innate immune cells, such as macrophages from CF patients express high levels of Mirc1/
Mir17–92 cluster and are associated with weak autophagy activity which is essential for
CFTR regulation, offering a potential new biomarker for autophagy-related functions in
immune cells. Although, the results with macrophages offer a reliable sample for testing the
Mirc1/Mir17–92 cluster as a biomarker, the routine derivation of immune cells from blood
samples can be laborious in a clinical setting. Therefore, we next determined the expression
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of the Mirc1/Mir17–92 cluster in readily available samples such as plasma and sputum. We
measured the cluster expression in frozen plasma samples to determine if the Mirc1/Mir17–
92 cluster could be detected in the absence of circulating phagocytes. Mirc1/Mir17–92
cluster expression was detected in low levels in both CF and non-CF plasma samples (Fig.
1B) with significant difference.

Author Manuscript

Given that sputum samples are non-invasively collected from CF patients on regular basis
and yield considerable amounts of biological material, we determined if Mirc1/Mir17–92
cluster expression was detectable in 28 CF sputum samples. Control sputum from non-CF
individuals was not available for comparison. All six cluster members were detectable in CF
sputum (Fig. 1C). There was significantly higher expression of all cluster members in CF
sputum compared to CF plasma (Fig. 1C). Therefore, although plasma samples do not
demonstrate substantial differences between CF and non-CF individuals, sputum samples
exhibit high levels of Mirc1/Mir17–92 cluster that may reflect disease prognosis.
3.3. Sputum Mirc1/Mir17–92 cluster expression correlates with lung function
In order to determine if Mirc1/Mir17–92 cluster expression in sputum samples correlated
with clinical outcomes, both plasma and sputum expression levels of Mirc1/Mir17–92
cluster were analyzed for their correlation with index lung function (FEV1, FVC), BMI, and
age. Sputum concentrations for all six cluster members correlated with FVC (rho range
−0.389–−0.545, Mir 92a) (Fig. 2A), FEV1 (rho range −0.392–−0.503), and age (rho range
0.44–0.528, Mir 92a) shown in Fig. 2B. Notably, there was a greater correlation of cluster
expression with age, compared to FVC and age (Fig. 2C, rho = −0.319, p value 0.005).

Author Manuscript

3.4. Mirc1/Mir17–92 cluster expression correlates with the presence of pulmonary
exacerbations
There are no reliable existing biomarkers in clinical use to detect early stages of PEx in
patients with CF. PEx are associated with acute morbidity and rapid lung function decline,
and hence, it is important to detect PEX at early stages to better prevent the deterioration of
lung functions. Due to the wide spread of cluster expression in sputum observed (Fig. 1C),
we determined if Mirc1/Mir17–92 cluster expression in sputum correlated with PEx status.
Comparing exacerbated and non-exacerbated subjects, we found that all six members of the
Mirc1/Mir17–92 cluster expression were significantly elevated in subjects at the start of a
PEx compared to non-exacerbated subjects (Fig. 3A). The effect of exacerbation was still
significant for all six members after controlling for sex and age using ANCOVA. These
results indicate that the Mirc1/Mir17–92 cluster expression may be useful in a model for
detecting PEx.

Author Manuscript

3.5. Lumacaftor/Ivacaftor do not alter Mirc1/Mir17–92 cluster expression
Lumacaftor/Ivacaftor is a combination of CFTR modulators that was approved in July 2015
by the United States Food and Drug Administration for CF patients that are homozygous for
the F508del mutation. Lumacaftor/Ivacaftor demonstrated modest increases in patient lung
function and decreases in PEx in clinical trials [19]. Opinions regarding the clinical utility of
this new drug combination remain guarded [20] and there is few existing data regarding its
efficacy and immunologic effects in CF patients. We measured Mirc1/Mir17–92 cluster
J Cyst Fibros. Author manuscript; available in PMC 2019 July 01.
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expression in sputum from 17 subjects before and 6 months after Lumacaftor/Ivacaftor
initiation to determine if treatment initiation impacted cluster expression (Fig. 3B). There
was an overall wide spread of data points for the other individual Mirs pre- and postLumacaftor/Ivacaftor initiation but there was no significant difference between pre-and posttreatment. Outliers were noted in subjects who were exacerbated at drug initiation, similar to
sputum levels previously presented. Therefore, in congruence with modest clinical
improvement observed in clinical trials, Lumacaftor/Ivacaftor treatment did not significantly
affect the expression of the Mirc1/Mir17–92 cluster.

4. Discussion

Author Manuscript

There is a clear need for reliable, non-invasive and feasible methods to predict and detect
PEx in CF patients beyond the limitations of the current practice of monitoring acute
deterioration in clinical symptoms and pulmonary function, especially where timely
intervention is critical for improved patient outcomes and to identify those at risk for
accelerated deterioration in lung function. Finding biomarkers that are representative of
overall prognosis and response to treatment will greatly improve the delivery of personalized
care for patients with CF. Importantly; in this study we demonstrate that elevated expression
of Mirc1/Mir17–92 cluster in sputum of CF patients is associated with PEx and increases
with age.

Author Manuscript

Our understanding of Mirs and their role in different pathologies is increasing rapidly.
During the past two decades, 2588 mature Mirs have been described in humans. The roles of
Mirs have been described in several diseases, including cancers, [21–23] coronary diseases,
[24,25] autoimmune diseases, [26–28] and viral infections [29,30]. Although several studies
have emerged describing Mir dysregulation in CF (reviewed in [31]), Mir involvement in CF
needs further investigation and elucidation. Several studies involving Mirs in CF have
focused on their impact on CFTR expression. For instance, elevated Mir494 represses CFTR
expression, [32,33] whereas that of Mir138 increases its level [34]. Other studies have
assessed Mir-mediated regulation of inflammation in CF patients [35]. For instance Mir126
is highly expressed in the lung yet downregulated in CF bronchial epithelial cells which
correlates with a significant upregulation of TOM1 mRNA [36] which modulates
inflammatory response [37]. Mir17 overexpression in CF airway epithelial cells decreases
interleukin-8 production [38]. Few studies reported the alteration of expression of Mirs
affecting immune function and inflammation in CF [35,39].

Author Manuscript

Although Mirs predominantly reside intracellularly, they can stably exist in extracellular
environments such as in serum, plasma, semen, cerebrospinal fluid and urine. This robust
stability, together with demonstrated organ- and disease-specific expression, enables Mirs to
act as potential non-invasive biomarkers for the detection and diagnosis of disease
conditions. As revealed from the current study, the Mirc1/Mir17–92 cluster was expressed
widely in both circulating CF cells and systemic and airway biologic samples, indicating its
robustness as a marker of both systemic and local lung disease. As sputum may not be
readily available in young or non-expectorating subjects, the optimal specimen for Mirc1/
Mir17–92 cluster expression in CF patients where sputum is unable to be induced remains to
be determined. Additionally, Mirc1/Mir17–92 cluster expression is minimally impacted by
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initiation of treatment with the CFTR modulator Ivacaftor/Lumacaftor. This finding
corroborates with the lack of clinical improvement of this drug combination in several CF
patients. Therefore, further studies are needed to determine if Mirc1/Mir17–92 cluster
expression represents a prognostic marker of biologic response to current and newly
developed CFTR modulators that offer significant improvement of clinical symptoms in the
CF population. We believe this is highly likely as we have shown that therapeutic downregulation of the Mirc1/Mir17–92 cluster improves CFTR function [13]. This effect is
mediated by improvement of autophagy activity when the expression of the cluster is
corrected [13]. Therefore, the level of expression of the Mirc1/Mir17–92 cluster may
reciprocally correlate with the response to effective CFTR corrector therapies.

Author Manuscript

This is not the first report of differential expression of members of the Mirc1/Mir17–92
cluster. Another study demonstrated the diverse mature levels of individual Mirc1/Mir17–92
cluster members in different cell lines [40]. Together, our data and that of others suggest the
existence of the molecular mechanisms responsible for differential maturation of individual
Mir cluster members within one cluster [18,41]. In fact, the expression and function of Mirs
are regulated at three levels: transcription, processing, and subcellular localization [42]. At
the level of transcription, miRNA expression is controlled by many factors including
chromatin modifications, DNA methylation, and activity of transcription factors [43]. Our
data and that of others also suggest the presence of an alternative transcript to account for
variable expression levels of individual miRNAs [44]. Additionally, Mir-related single
nucleotide polymorphisms (SNPs) [45], including SNPs in Mir genes and target sites,
function as regulatory SNPs to affect the phenotypes and disease susceptibility [46]. SNPs
that affect miRNA binding and function are being increasingly reported [47].

Author Manuscript

Notably, several studies demonstrated that CF patients have an increased risk of cancer
especially in the digestive tract [48,49]. Downregulation of CFTR mRNA gene expression
was also included in a prognostic predictor gene set for poor prognosis in colorectal cancer
[50]. Another study for early colon screening of adult CF patients revealed a high incidence
of colon tumors, especially in males [51]. Mir17 is overexpressed in CF macrophages (this
study) and epithelial cells [38], and is correlated with gastric cancer [52]. Interestingly, a
recent meta-analysis study towards high-expression of Mirc1/Mir17–92 cluster has indicated
poor prognosis of various cancers [53,54]. Therefore, our finding that Mirc1/Mir17–92
cluster is highly expressed in CF, may explain the increased incidence of adenomas and
cancer in CF [55,56].

Author Manuscript

Our study shows that the expression of Mirs within the Mirc1/Mir17–92 cluster is increased
with age. Given that high expression level of Mirc1/Mir17–92 cluster is a predictor of poor
overall survival in patients with cancer [53,57], it is possible that the elevated level of Mirc1/
Mir17–92 cluster correlates with poor prognosis of cancer in the CF population.
In summary, Mirc1/Mir17–92 cluster is highly expressed in CF cells and biologic fluids and
correlates with respiratory status, age and PEx.
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Fig. 1.
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CF patients have elevated Mirc1/Mir17–92 cluster expression. A) Human neutrophils were
isolated from peripheral blood samples from healthy controls and CF patients with at least
one F508del mutation and a second class I or class II CFTR mutation. Mirc1/Mir17–92
cluster expression was determined by qRT-PCR, n = 8 for the control group and n = 5 for the
CF group, significance determined with Mann-Whitney U tests. Mir17 p value 0.94, Mir18a
p value 1, Mir 19a p value 0.47, Mir19b p value 1, Mir20a p value 0.83, and Mir92 p value
0.94. B) Human plasma was isolated from peripheral blood samples from CF patients and
healthy controls. Mirc1/Mir17–92 cluster expression was determined by qRT-PCR, n = 55
for the CF group and n = 49 for the non-CF group. Mir17 p value 0.47, Mir18a p value 0.63,
Mir 19a p value 0.22, Mir19b p value 0.22, Mir20a p value 0.43, and Mir92a p value 0.14.
C) Sputum was obtained from 29 CF patients. Mirc1/Mir17–92 cluster expression was
determined by qRT-PCR and expression levels compared to plasma levels from 1B. Mir17 p
value < 0.0001, Mir18a p value < 0.0001, Mir 19a p value < 0.0001, Mir19b p value <
0.0001, Mir20a p value < 0.0001, and Mir92 p value < 0.0001. “*” = p value < 0.05, “**” =
p value < 0.01, “***” = p value < 0.001.
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Fig. 2.

Sputum Mirc1/Mir17–92 cluster expression correlates with lung function. A) Correlation
plot for sputum Mir92a expression and forced vital capacity (FVC) from 27 patients with
CF. Spearman’s rank correlation coefficient (rho) = −0.545, p value = 0.003. B) Correlation
plot for sputum Mir92a expression and age from 28 patients with CF. Spearman’s rank
correlation coefficient (rho) = 0.528, p value = 0.004. C) Correlation plot for FVC and age
from 77 patients with CF. Pearson correlation coefficient (r) = −0.319, p value = 0.005.
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Sputum Mirc1/Mir17–92 cluster expression correlates with pulmonary exacerbations. A)
Sputum samples cluster expression levels were grouped according to the presence or
absence of a pulmonary exacerbation in CF patients. Mir17 p value = 0.006, Mir18a p value
= 0.034, Mir 19a p value = 0.023, Mir19b p value = 0.013, Mir20a p value = 0.043, and
Mir92a p value = 0.049. B) Sputum from CF patients at baseline and 6 months-postLumacaftor/Ivacaftor initiation were obtained. Mirc1/Mir17–92 cluster expression was
determined by qRT-PCR, n = 16 for each group. Expression levels were compared for each
subject pre- and post-drug initiation. Mir17 p value = 0.59, Mir18a p value = 0.23, Mir 19a p
value = 0.63, Mir19b p value = 0.63, Mir20a p value =0.37, and Mir92 p value = 0.05. *” =
p value < 0.05, “**” = p value < 0.01, “***” = p value < 0.001.
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Cohort demographics.
CF

Controls

n=

76

49

Females (%)

40.9

66.7

Age (years, st dev)

26.6 ± 8.9

33.3 ± 10.3

Caucasian (%)

100

100

Pancreatic insufficiency (%)

93.0

0

F508del homozygous

80.9

N/A

F508del heterozygous

15.5

N/A

FEV1 (% predicted, st dev)

60.9 ± 22.2

N/A

BMI (st dev)

21.7 ± 3.7

N/A

Genotype (%)
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